Literature DB >> 29551768

Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in a mouse model of chronic liver injury.

Haksier Ehedego1, Antje Mohs1, Bettina Jansen1, Kanishka Hiththetiya2, Piotr Sicinski3, Christian Liedtke1, Christian Trautwein4.   

Abstract

Chronic liver injury triggers liver fibrosis and hepatocellular carcinoma (HCC), the third leading cause of cancer-related mortality. Cyclin E1 (CcnE1, formerly designated Cyclin E) is a regulatory subunit of the Cyclin-dependent kinase 2 (CDK2). It is overexpressed in approximately 70% of human HCCs correlating with poor prognosis, while the relevance of its orthologue Cyclin E2 (CcnE2) is unclear. Hepatocyte-specific deletion of NF-kappa-B essential modulator (NEMOΔhepa) leads to chronic hepatitis, liver fibrosis, and HCC as well as CcnE upregulation. To this end, we generated NEMOΔhepa/CcnE1-/- and NEMOΔhepa/CcnE2-/- double knockout mice and investigated age-dependent liver disease progression in these animals. Deletion of CcnE1 in NEMOΔhepa mice decreased basal liver damage and reduced spontaneous liver inflammation in young mice. In contrast, loss of CcnE2 did not affect liver injury in NEMOΔhepa livers pointing to a unique, non-redundant function of CcnE1 in chronic hepatitis. Accordingly, basal compensatory hepatocyte proliferation in NEMOΔhepa mice was reduced by concomitant ablation of CcnE1, but not after loss of CcnE2. In aged NEMOΔhepa mice, loss of CcnE1 resulted in significant reduction of liver tumorigenesis, while deletion of CcnE2 had no effect on HCC formation. CcnE1, but not its orthologue CcnE2, substantially contributes to hepatic inflammatory response, liver disease progression, and hepatocarcinogenesis in NEMOΔhepa mice.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29551768      PMCID: PMC6388396          DOI: 10.1038/s41388-018-0181-8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Cyclin E ablation in the mouse.

Authors:  Yan Geng; Qunyan Yu; Ewa Sicinska; Manjusri Das; Jürgen E Schneider; Shoumo Bhattacharya; William M Rideout; Roderick T Bronson; Humphrey Gardner; Piotr Sicinski
Journal:  Cell       Date:  2003-08-22       Impact factor: 41.582

3.  Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation.

Authors:  B E Clurman; R J Sheaff; K Thress; M Groudine; J M Roberts
Journal:  Genes Dev       Date:  1996-08-15       Impact factor: 11.361

4.  Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice.

Authors:  Jörg-Martin Bangen; Linda Hammerich; Roland Sonntag; Maike Baues; Ute Haas; Daniela Lambertz; Thomas Longerich; Twan Lammers; Frank Tacke; Christian Trautwein; Christian Liedtke
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

5.  NEMO expression in human hepatocellular carcinoma and its association with clinical outcome.

Authors:  Ariane Aigelsreiter; Johannes Haybaeck; Silvia Schauer; Tobias Kiesslich; Kira Bettermann; Antonia Griessbacher; Tatjana Stojakovic; Thomas Bauernhofer; Hellmut Samonigg; Peter Kornprat; Carolin Lackner; Martin Pichler
Journal:  Hum Pathol       Date:  2011-12-15       Impact factor: 3.466

6.  Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells.

Authors:  Tiziana Parisi; Andreas R Beck; Nathalie Rougier; Tom McNeil; Linda Lucian; Zena Werb; Bruno Amati
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

7.  Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma.

Authors:  Kaiyi Li; Shiaw-Yih Lin; F Charles Brunicardi; Philip Seu
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  NF-κB essential modifier is required for hepatocyte proliferation and the oval cell reaction after partial hepatectomy in mice.

Authors:  Yann Malato; Haksier Ehedego; Malika Al-Masaoudi; Francisco Javier Cubero; Jörn Bornemann; Nikolaus Gassler; Christian Liedtke; Naiara Beraza; Christian Trautwein
Journal:  Gastroenterology       Date:  2012-08-23       Impact factor: 22.682

9.  Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis.

Authors:  Sharon Pok; Victoria Wen; Nicholas Shackel; Amber Alsop; Pawan Pyakurel; Aude Fahrer; Geoffrey C Farrell; Narci C Teoh
Journal:  J Gastroenterol Hepatol       Date:  2013-09       Impact factor: 4.029

10.  Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage.

Authors:  Naiara Beraza; Yann Malato; Leif E Sander; Malika Al-Masaoudi; Julia Freimuth; Dieter Riethmacher; Gregory J Gores; Tania Roskams; Christian Liedtke; Christian Trautwein
Journal:  J Exp Med       Date:  2009-07-27       Impact factor: 14.307

View more
  9 in total

1.  Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.

Authors:  Roland Sonntag; Nives Giebeler; Yulia A Nevzorova; Jörg-Martin Bangen; Dirk Fahrenkamp; Daniela Lambertz; Ute Haas; Wei Hu; Nikolaus Gassler; Francisco Javier Cubero; Gerhard Müller-Newen; Ali T Abdallah; Ralf Weiskirchen; Fabio Ticconi; Ivan G Costa; Mariano Barbacid; Christian Trautwein; Christian Liedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-27       Impact factor: 11.205

2.  Scinderin suppresses cell proliferation and predicts the poor prognosis of hepatocellular carcinoma.

Authors:  Bin Zhou; Tian-Wei Chen; Ya-Bo Jiang; Xu-Biao Wei; Chong-De Lu; Jing-Jing Li; Dong Xie; Shu-Qun Cheng
Journal:  Oncol Lett       Date:  2020-01-08       Impact factor: 2.967

Review 3.  Cyclin E in normal physiology and disease states.

Authors:  Chen Chu; Yan Geng; Yu Zhou; Piotr Sicinski
Journal:  Trends Cell Biol       Date:  2021-05-27       Impact factor: 21.167

Review 4.  Structural insights into the functional diversity of the CDK-cyclin family.

Authors:  Daniel J Wood; Jane A Endicott
Journal:  Open Biol       Date:  2018-09       Impact factor: 6.411

5.  Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin.

Authors:  Chao Zhang; Qiang Zhu; Jianzhong Gu; Shan Chen; Qian Li; Liping Ying
Journal:  Biosci Rep       Date:  2019-06-04       Impact factor: 3.840

Review 6.  Nuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy.

Authors:  Xiaomin Liu; Yang Shao; Jinbao Zhou; Guangren Qian; Zhongliang Ma
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-18       Impact factor: 8.886

7.  Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7.

Authors:  Jinbiao Chen; Yang Zhao; Fan Zhang; Jia Li; Jade A Boland; Ngan Ching Cheng; Ken Liu; Jessamy C Tiffen; Patrick Bertolino; David G Bowen; Andreas Krueger; Leszek Lisowski; Ian E Alexander; Mathew A Vadas; Emad El-Omar; Jennifer R Gamble; Geoffrey W McCaughan
Journal:  Cell Mol Life Sci       Date:  2022-07-22       Impact factor: 9.207

8.  Advances on molecular mechanism of hepatitis B virus-induced hepatocellular carcinoma.

Authors:  Yiming Shao; Lide Su; Rui Hao; Qianqian Wang; Hua Naranmandura
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-02-25

Review 9.  Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma.

Authors:  Daisuke Uchida; Akinobu Takaki; Atsushi Oyama; Takuya Adachi; Nozomu Wada; Hideki Onishi; Hiroyuki Okada
Journal:  Nutrients       Date:  2020-05-28       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.